PURPOSE: This retrospective analysis aimed to evaluate the stability of spinal metastases in malignant melanoma patients following radiotherapy (RT), and to assess prognostic factors for survival. METHODS: Forty-one patients with malignant melanoma and osteolytic spinal bone metastases were irradiated at the university clinics of Heidelberg and Mainz between July 2003 and October 2013. Three and six months after palliative RT, only 20 and 15 patients, respectively, were still alive and were therefore assessed for spinal stability using the Taneichi score based on CT imaging. Additionally, overall survival (OS) and bone survival (BS) rates as well as prognostic factors for BS were evaluated for all study patients. RESULTS: Before RT, 19 patients (46.3%) were rated unstable. In the surviving patients, none of the unstable metastases were classified as stable 6 months after RT. Five-year OS was 23.3% and median BS was 4 months (range 0.5-29.8). Accordingly, only 36.6% of the patients were still alive 6 months after RT. Karnofsky performance score (KPS) <70%, visceral metastases and more than one bone metastasis were significantly predictive of poor BS. CONCLUSIONS: Our study population was characterized by poor BS and a lack of benefit with regard to stabilization of initially unstable spinal bone metastases 3 and 6 months after RT. This applies in particular to patients with a KPS <70%, visceral metastases and multiple bone metastases. Given the limited life expectancy, short fractionated treatment schedules of RT may be preferred in this population.
PURPOSE: This retrospective analysis aimed to evaluate the stability of spinal metastases in malignant melanomapatients following radiotherapy (RT), and to assess prognostic factors for survival. METHODS: Forty-one patients with malignant melanoma and osteolytic spinal bone metastases were irradiated at the university clinics of Heidelberg and Mainz between July 2003 and October 2013. Three and six months after palliative RT, only 20 and 15 patients, respectively, were still alive and were therefore assessed for spinal stability using the Taneichi score based on CT imaging. Additionally, overall survival (OS) and bone survival (BS) rates as well as prognostic factors for BS were evaluated for all study patients. RESULTS: Before RT, 19 patients (46.3%) were rated unstable. In the surviving patients, none of the unstable metastases were classified as stable 6 months after RT. Five-year OS was 23.3% and median BS was 4 months (range 0.5-29.8). Accordingly, only 36.6% of the patients were still alive 6 months after RT. Karnofsky performance score (KPS) &lt;70%, visceral metastases and more than one bone metastasis were significantly predictive of poor BS. CONCLUSIONS: Our study population was characterized by poor BS and a lack of benefit with regard to stabilization of initially unstable spinal bone metastases 3 and 6 months after RT. This applies in particular to patients with a KPS &lt;70%, visceral metastases and multiple bone metastases. Given the limited life expectancy, short fractionated treatment schedules of RT may be preferred in this population.
Authors: Francesco Mannavola; Mario Mandala; Annalisa Todisco; Vanna Chiarion Sileni; Marco Palla; Alessandro Marco Minisini; Laura Pala; Francesca Morgese; Lorenza Di Guardo; Luigia Stefania Stucci; Michele Guida; Alice Indini; Pietro Quaglino; Virginia Ferraresi; Riccardo Marconcini; Maria Chiara Tronconi; Ernesto Rossi; Olga Nigro; Marcella Occelli; Alessio Cortellini; Silvia Quadrini; Giuseppe Palmieri; Jacopo Pigozzo; Paolo Antonio Ascierto; Maria Grazia Vitale; Sabino Strippoli; Pier Francesco Ferrucci; Rossana Berardi; Giovanni Randon; Pietro Cardone; Giovanni Schinzari; Franco Silvestris; Marco Tucci Journal: Front Oncol Date: 2020-09-15 Impact factor: 6.244
Authors: Tilman Bostel; Robert Förster; Ingmar Schlampp; Tania Sprave; Thomas Bruckner; Nils Henrik Nicolay; Stefan Ezechiel Welte; Jürgen Debus; Harald Rief Journal: Radiat Oncol Date: 2017-07-11 Impact factor: 3.481
Authors: Eva Meyerhof; Tanja Sprave; Stefan Ezechiel Welte; Nils H Nicolay; Robert Förster; Tilman Bostel; Thomas Bruckner; Ingmar Schlampp; Jürgen Debus; Harald Rief Journal: Trials Date: 2017-03-03 Impact factor: 2.279
Authors: Tilman Bostel; Robert Förster; Ingmar Schlampp; Tanja Sprave; Sati Akbaba; Daniel Wollschläger; Jürgen Debus; Arnulf Mayer; Heinz Schmidberger; Harald Rief; Nils Henrik Nicolay Journal: Strahlenther Onkol Date: 2019-06-25 Impact factor: 3.621
Authors: Tilman Bostel; Sati Akbaba; Daniel Wollschläger; Tristan Klodt; Laura Oebel; Arnulf Mayer; Sophia Drabke; Tanja Sprave; Jürgen Debus; Robert Förster; Harald Rief; Alexander Rühle; Anca-Ligia Grosu; Heinz Schmidberger; Nils H Nicolay Journal: Front Oncol Date: 2021-10-19 Impact factor: 6.244